-+ 0.00%
-+ 0.00%
-+ 0.00%

Aligos Therapeutics Q1 EPS $(2.11) Beats $(2.74) Estimate, Revenue $311.00K Miss $333.33K Estimate

Benzinga·05/06/2025 12:02:19
Listen to the news
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.11) per share which beat the analyst consensus estimate of $(2.74) by 22.99 percent. This is a 62.19 percent increase over losses of $(5.58) per share from the same period last year. The company reported quarterly sales of $311.00 thousand which missed the analyst consensus estimate of $333.33 thousand by 6.70 percent. This is a 68.46 percent decrease over sales of $986.00 thousand the same period last year.